The Technical Analyst
Burning Rock Biotech Ltd [BNR]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Burning Rock Biotech Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.24% $0.800
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 82.10 mill |
| EPS: | -0.960 |
| P/E: | -0.830 |
| Earnings Date: | May 27, 2024 |
| SharesOutstanding: | 102.64 mill |
| Avg Daily Volume: | 0.0501 mill |
| RATING 2024-04-15 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.830 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.830 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.731 - 0.869 ( +/- 8.63%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.800
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.800
Forecast 2: 16:00 - $0.800
Forecast 3: 16:00 - $0.800
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.800 (5.24% ) |
| Volume | 0.0442 mill |
| Avg. Vol. | 0.0501 mill |
| % of Avg. Vol | 88.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BNR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BNR
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Latest Press Releases
2024-03-28 17:16:00 - Press Release
Burning Rock Reports Fourth Quarter And Full Year 2023 Financial Results
Guangzhou, china, march 28, 2024 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today reported financial results for the three months and the year ended december 31, 2023. 2023 business overview and recent updates corporate updates completed profitability-driven organizational optimization, execution towards profitability well underway early detection following the breakthrough device designation granted by the us food and drug administration (fda) for our overc™ multi-cancer detection blood test (mcdbt) in january 2023, our overc™ mcdbt also received the breakthrough device designation by china's national medical products administration (nmpa) in october 2023, making it the only test globally that has received breakthrough device designation from both the fda and the nmpa.
2024-01-04 01:03:00 - Press Release
Burning Rock Announces Receipt Of Notification From Nasdaq
Guangzhou, china, jan. 04, 2024 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today announced that it has received written notification from the staff of the listing qualifications department of the nasdaq stock market llc (“nasdaq”) dated december 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the company's american depositary shares (the “adss”) was below the minimum bid price of us$1.00 per share requirement set forth in nasdaq listing rule 5450(a)(1)...
2023-12-19 21:35:00 - Press Release
Burning Rock Announces Results Of 2023 Annual General Meeting
Guangzhou, china, dec. 19, 2023 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focusing on the application of next generation sequencing (ngs) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the company's 2023 annual general meeting held today were duly passed. specifically, the shareholders passed the following resolutions: to ratify the appointment of ernst & young hua ming llp as auditor of the company for the fiscal year ending december 31, 2023 and to authorize the directors of the company to determine the remuneration of the auditor; to re-elect wendy hayes, min-jui richard shen and zhihong (joe) zhang as directors of the company; and to authorize each of the directors of the company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
2023-11-30 01:25:00 - Press Release
Burning Rock Reports Third Quarter 2023 Financial Results
Guangzhou, china, nov. 30, 2023 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today reported financial results for the three months ended september 30, 2023. recent business updates therapy selection and minimal residual disease (mrd) personalized minimal residual disease (mrd) product, brprophettm supports advancement in early-stage non-small cell lung cancer treatment, with results published in the cancer cell in september 2023.
2023-11-22 02:04:00 - Press Release
Burning Rock Announces 2023 Annual General Meeting To Be Held On December 20, 2023
Guangzhou, china, nov. 22, 2023 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focusing on the application of next generation sequencing (ngs) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“agm”) on december 20, 2023 at 10:00 a.m. (local time) at the company's shanghai office at 6/f, building 10c, pujiang smart plaza, no.
Latest News
2023-11-30 09:26:05 - Seeking Alpha
Burning Rock Biotech Limited (BNR) Q3 2023 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q3 2023 Earnings Call Transcript November 30, 2023 7:00 AM ET Company Participants Yusheng Han - Founder, Chairman and Chief Executive Officer Leo Li - CFO Joe Zhang - CTO Conference Call Participants Operator Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expect, anticipate, future, intends, plans, believes, estimates, target, confident and similar statements.
2023-11-20 20:55:00 - GlobeNewsWire
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
GUANGZHOU, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2023 before the U.S. market opens on November 30, 2023. Following the release, company management will host a conference call at 7:00 a.m.
2023-08-31 15:12:10 - Seeking Alpha
Burning Rock Biotech Limited (BNR) Q2 2023 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q2 2023 Earnings Conference Call August 31, 2023 8:00 AM ET Company Participants Yusheng Han - Founder, Chairman and CEO Leo Li - CFO Conference Call Participants Operator Good morning, ladies and gentlemen. Thank you for standing by.
2023-08-04 03:27:00 - GlobeNewsWire
Burning Rock Provides Second Quarter 2023 Business Updates and Schedules Earnings Release on August 31, 2023
GUANGZHOU, China, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2023 before the U.S. market opens on August 31, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the second quarter of 2023.
2023-05-30 10:55:40 - Zacks Investment Research
Is Burning Rock Biotech (BNR) Outperforming Other Business Services Stocks This Year?
Here is how Burning Rock Biotech Limited Sponsored ADR (BNR) and Green Dot (GDOT) have performed compared to their sector so far this year.
2023-05-30 10:25:19 - Seeking Alpha
Burning Rock Biotech Limited (BNR) Q1 2023 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q1 2023 Earnings Conference Call May 30, 2023 8:00 AM ET Company Participants Yusheng Han - Founder, Chairman & CEO Leo Li - CFO Joe Zhang - CTO Conference Call Participants Alexis Yan - Morgan Stanley Operator Good day, and thank you, for standing by. Welcome to the Burning Rock's 2023 Q1 Earnings Conference Call.
2023-04-27 01:01:00 - GlobeNewsWire
Burning Rock Provides First Quarter 2023 Business Updates and Schedules Earnings Release on May 30, 2023
GUANGZHOU, China, April 27, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2023 before the U.S. market opens on May 30, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2023.
2023-03-07 03:38:00 - GlobeNewsWire
Burning Rock Schedules Fourth Quarter and Full Year 2022 Earnings Release on March 28, 2023
GUANGZHOU, China, March 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the fourth quarter and full year 2022 before the U.S. market opens on March 28, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the fourth quarter and full year 2022.
2022-11-21 13:32:27 - Zacks Investment Research
Burning Rock Biotech Limited Sponsored ADR (BNR) Upgraded to Buy: What Does It Mean for the Stock?
Burning Rock Biotech Limited Sponsored ADR (BNR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-11-16 11:41:03 - Seeking Alpha
Burning Rock Biotech (BNR) Q3 2022 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q3 2022 Earnings Conference Call November 16, 2022 8:30 AM ET Company Participants Yusheng Han - Chairman and CEO Dr. Shaokun Chuai - COO Leo Li - CFO Conference Call Participants Alexis Yan - Morgan Stanley Max Masucci - Cowen & Company Operator Good day and thank you for standing by. Welcome to the Burning Rock 2022 Third Quarter Earnings Conference Call.